de Bruijn, Ino https://orcid.org/0000-0001-5427-4750
Nikolov, Milen https://orcid.org/0000-0003-2647-3255
Lau, Clarisse
Clayton, Ashley https://orcid.org/0000-0002-4570-2706
Gibbs, David L. https://orcid.org/0000-0003-1121-5114
Mitraka, Elvira
Pozhidayeva, Dar’ya https://orcid.org/0000-0002-8912-2682
Lash, Alex https://orcid.org/0000-0003-3787-1590
Sumer, Selcuk Onur https://orcid.org/0000-0001-9726-9441
Altreuter, Jennifer https://orcid.org/0000-0001-6545-6496
Anton, Kristen https://orcid.org/0000-0002-0773-4141
DeFelice, Mialy https://orcid.org/0000-0002-7197-6292
Li, Xiang https://orcid.org/0000-0003-2782-2250
Lisman, Aaron
Longabaugh, William J. R. https://orcid.org/0000-0002-4192-6315
Muhlich, Jeremy https://orcid.org/0000-0002-0811-637X
Santagata, Sandro https://orcid.org/0000-0002-7528-9668
Nandakumar, Subhiksha https://orcid.org/0000-0003-0258-3484
Sorger, Peter K. https://orcid.org/0000-0002-3364-1838
Suver, Christine https://orcid.org/0000-0002-2986-385X
Doan, Xengie https://orcid.org/0000-0002-8245-1555
Guinney, Justin https://orcid.org/0000-0003-1477-1888
Schultz, Nikolaus https://orcid.org/0000-0002-0131-4904
Taylor, Adam J. https://orcid.org/0000-0003-0501-8886
Thorsson, Vésteinn https://orcid.org/0000-0002-3498-2378
Cerami, Ethan https://orcid.org/0009-0009-2340-4490
Eddy, James A. https://orcid.org/0000-0001-9758-0176
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24CA233243, P30CA008748, U24CA233243, U24CA233243, U24CA233243, U24CA233243, U24CA233243, U24CA233243, U24CA233243, U24CA233243, P30CA008748, U24CA233243, U24CA233243, U24CA233243, U24CA233243, P30CA008748, U24CA233243, P30CA008748, U24CA233243, U2CCA233262, U2CCA233262, U24CA233243, P30CA008748, U2CCA233262, U24CA233243, U24CA233243, U24CA233243, U24CA233243, P30CA008748, U24CA233243, U24CA233243, U24CA233243, U24CA233243)
Article History
Received: 11 July 2024
Accepted: 26 February 2025
First Online: 31 March 2025
Competing interests
: P.K.S. is a cofounder and member of the BOD of Glencoe Software, member of the BOD for Applied BioMath and a member of the SAB for RareCyte, NanoString, Reverb Therapeutics and Montai Health; he holds equity in Glencoe, Applied BioMath and RareCyte. S.S. is a consultant for RareCyte. The other authors declare no competing interests